CTIS2024-512865-15-00进行中（未招募）1 期
A PHASE 2, RANDOMIZED, BLINDED, PLACEBOCONTROLLED, STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOMETRICS, AND EFFICACY OF DNTH103 IN ADULTS WITH GENERALIZED MYASTHENIA GRAVIS (MAGIC) - DNTH103-MG-201
Dianthus Therapeutics Inc.0 个研究点目标入组 60 人开始时间: 2024年3月29日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Must have given written informed consent before any study-related activities are carried out and must be able to understand the full nature and purpose of the study, including possible risks and adverse effects., Participants must be receiving at least 1 but not more than 3 of the following immunosuppressant medications at Screening, provided they have a stable daily dose for the minimum periods outlined below and maintain throughout the study: a. If taking oral corticosteroids, must have been taking for at least 4 weeks (28 days) prior to randomization, with doses not to exceed an average of 40 mg/day (280 mg/week) of prednisone or its equivalent; b. If taking azathioprine, must have been taking for at least 6 months (180 days) at time of randomization with a stable dose for at least 2 months (60 days) prior to randomization; c. If taking other immunosuppressants, must have been on other immunosuppressants (such as cyclosporin, mycophenolate mofetil, cyclophosphamide, or methotrexate) for at least 3 months (90 days) at time of randomization with a stable dose for at least 1 month (30 days) prior to randomization., Female participants must: a. Be of nonchildbearing potential, ie, surgically sterilized via laparoscopic methods at least 6 weeks before Screening, if surgically sterilized via open abdominal surgery, at least 12 weeks before Screening or postmenopausal (where postmenopausal is defined as no menses for 12 months without an alternative medical cause and a follicle-stimulating hormone [FSH] level = 40 IU/L at Screening), or b. If of childbearing potential, must agree not to donate ova, not to attempt to become pregnant and, if engaging in sexual intercourse with a male partner, must agree to use a highly effective method of contraception from signing the informed consent form throughout the study until the end of the Safety Follow-up period, or longer if required in accordance with local requirements., Male participants must be surgically sterile for at least 90 days prior to Screening or agree not to donate sperm and, if engaging in sexual intercourse with a female partner who could become pregnant, must agree to use an acceptable method of contraception from signing the informed consent form throughout the study until the end of the Safety Follow-up period, or longer if required in accordance with local requirements., No clinically significant abnormalities (in the opinion of the Investigator) during Screening, including: a. No clinically significant findings in serum chemistry, hematology, coagulation, and urinalysis tests. b. Triplicate 12-lead electrocardiogram (ECG) with a mean QT interval corrected using the Fridericia method (QTcF) = 450 msec for males and = 470 msec for females and no clinically significant abnormalities. The triplicate 12-lead ECG assessment may be repeated once, if abnormal values were recorded in any of the 3 readings completed in the first instance, at the discretion of the PI. Electrocardiogram findings outside of normal ranges may be considered acceptable if determined by the Investigator to be not clinically significant., Be willing and able to comply with all study assessments and adhere to the protocol schedule and restrictions., Adult males and females, 18 to 75 years of age (inclusive) at Screening., Weight range between 40-120 kg at Screening., Diagnosed with gMG at least 3 months (90 days) before the Screening visit, confirmed as specified in inclusion criterion #5 below., Diagnosis of gMG
排除标准
- •History or presence of significant medical/surgical condition including any acute illness or major surgery considered to be clinically significant or that could have potential impact on safety/efficacy or study procedures in the opinion of the Investigator., History of active malignancy within 5 years prior to Screening, except basal cell carcinoma of the skin, curatively resected squamous cell carcinoma of the skin, cervical carcinoma in situ curatively treated or low-grade prostate adenocarcinoma for which appropriate management is observation alone., History of hospitalization for 24 hours or longer, excluding elective procedures, within the 6 weeks (42 days) prior to Screening., Liver test results elevated more than 2-fold above the upper limit of normal for gamma-glutamyl transferase, bilirubin (total), aspartate aminotransferase (AST) or alanine aminotransferase (ALT), unless a diagnosis of Gilbert syndrome. For history of Gilbert syndrome, the limit is extended to 3-fold above the upper limit of normal., Concurrent or previous use of the following medications within the time periods specified below. a. Rituximab within 6 months (180 days) prior to randomization (Day 1); b. Intravenous immunoglobulin (IVIg) and plasma exchange (PLEX) within 4 weeks (28 days) prior to randomization (Day 1)., Receipt of any live vaccine within 30 days prior to randomization (Day 1) or expected to receive a live vaccine during the study., Clinically significant drug or alcohol abuse in the opinion of the Investigator., Known hypersensitivity to any of the study drug ingredients., For persons of childbearing potential, a positive serum pregnancy test during Screening or a positive urine pregnancy test (with confirmatory serum pregnancy test) at randomization., Females who are breastfeeding or planning to breastfeed at any time during the study., Participation in another clinical study of an investigational drug within 90 days or 5 half-lives of the investigational agent (whichever is longer) prior to randomization (Day 1)., Clinical features that, in the opinion of the Investigator, are consistent with MG crisis/exacerbation at the time of the Screening visit or at any time between Screening and randomization., Any other overlapping condition for which the condition or treatment of the condition may affect the study assessments or outcomes., Any other condition, including mental illness or prior therapy that in the opinion of the Investigator would make the participant unsuitable for this study, including inability to cooperate fully with the requirements of the study protocol or likelihood of noncompliance with any study requirements., Diagnosis of SLE or family history (defined as a parent or sibling) of SLE., Diagnosis of an autoimmune disorder other than gMG. Exceptions for other autoimmune disorders (except SLE) may be granted following Medical Monitor review and approval on a case-by-case basis., An antinuclear antibodies (ANA) titer of = 1:320, or positive for both ANA (any titer) and anti-double stranded (ds) DNA antibodies., Known complement deficiency or history of positive titer for anti-C1 antibodies., Prior history (at any time) of N. meningitidis infection., Positive test results for active human immunodeficiency virus (HIV-1 or HIV-2), hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV) antibodies during Screening. Participants who have no evidence of cirrhosis, have completed a curative intent regimen for HCV, and are deeme
研究者
相似试验
进行中（未招募）
1 期
A Study to Evaluate the Effects of RO6889450 (Ralmitaront) in Patients with Schizophrenia or Schizoaffective Disorder and Negative SymptomsEUCTR2020-004752-16-ESF. Hoffmann-La Roche Ltd220
已完成
2 期
BP40283SchizophreniaJPRN-jRCT2031200287Clinical trials information220
进行中（未招募）
1 期
A study to evaluate the benefit and safety of Luspatercept (ACE-536) in adults with Beta-Thalassemia who do not require regular red blood cell tranfusionson transfusion dependent ß-thalassemiaMedDRA version: 20.0Level: LLTClassification code 10074356Term: Non-transfusion dependent thalassemiaSystem Organ Class: 100000004850EUCTR2015-003225-33-ITCELGENE CORPORATIO150
进行中（未招募）
不适用
PHASE II RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER EFFICACY AND SAFETY STUDY OF TANEZUMAB AS ADD-ON THERAPY TO OPIOID MEDICATION IN PATIENTS WITH PAIN DUE TO BONE METASTASESPAIN DUE TO BONE METASTASESMedDRA version: 13.1Level: LLTClassification code 10049038Term: Metastatic bone painSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2008-005181-31-ATPfizer Inc., 235 East 42nd Street, New York, NY 1001758
进行中（未招募）
不适用
PHASE II RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER EFFICACY AND SAFETY STUDY OF TANEZUMAB AS ADD-ON THERAPY TO OPIOID MEDICATION IN PATIENTS WITH PAIN DUE TO BONE METASTASESPAIN DUE TO BONE METASTASESMedDRA version: 9.1Level: LLTClassification code 10049038Term: Metastatic bone painEUCTR2008-005181-31-HUPfizer Inc., 235 East 42nd Street, New York, NY 1001760